Fusion of the 5Ј half of the Ewing's sarcoma (ES) gene EWS with the DNA-binding domain of several transcription factors has been detected in many human tumors. The t(11;22)(q24;q12) chromosomal translocation is specifically linked to ES and primitive neuroectodermal tumors and results, in the majority of cases, in the fusion of the amino terminus of the EWS gene to the carboxyl-terminal DNA-binding domain of the FLI1 gene. The chimeric protein has been shown to be oncogenic, a potent transcriptional activator, and necessary for the maintenance of the Ewing's phenotype, making it an attractive target for gene therapy. In this study, we demonstrate that the ES transformed phenotype can be suppressed by chimeric transcriptional repressors containing the DNA-binding domain of FLI1 and the regulatory and repressor domain of ERF, a transcription suppressor and member of the ets gene family. The hybrid repressor is expressed at levels comparable with EWS/FLI1, does not affect EWS/FLI1 expression, and exhibits similar DNA-binding specificity but suppresses transcriptional activity. The FLI1/ERF repressor, like the wild-type ERF, is regulated by mitogen-activated protein kinase-dependent subcellular localization. Our data suggest that transformation by EWS/FLI1 may partially be due to activation of specific EWS/FLI1-regulated genes involved in cell proliferation.
A berrant expression and/or structural alteration of transcription factors have been suggested to be critical events in tumorigenic transformation.
1,2 The t(11;22)(q24;q12) chromosomal translocation, detected in the majority of Ewing's sarcoma (ES) and primitive neuroectodermal tumors, fuses the amino terminus of the EWS gene to the carboxyl terminus of the ets transcription factor family member FLI1. 3 In other ES and primitive neuroectodermal tumors, analogous translocations fuse the EWS gene to other members of the ets family, including ERG, 4 ETV-1, 5 E1AF, 6 and FEV, 7 members of the ERG and PEA3 subclasses of the family. 8, 9 In all of these fusions, the transactivating domain of the EWS gene is fused to the DNA-binding domain of an ets gene. It has been shown that the EWS/FLI1 fusion protein is a more potent transcriptional activator than FLI1 10, 11 and, in contrast to FLI1, is a transforming gene. 10 Both the transactivation domain of EWS and the ets-DNA-binding domain are required for transformation, 10 and the transactivation efficiency of different classes of EWS-FLI1 fusions has been reported to correlate with the behavior of tumors in vivo. 12 Furthermore, the transforming phenotype can be suppressed by blocking EWS-FLI1 production. [13] [14] [15] The parental EWS protein contains an RNA-binding domain and a transactivation domain and is similar to the TLS/FUS and hTAF II 68 members of the TET family of proteins that are able to interact with both TFIID and RNA polymerase II. 16 The EWS-FLI1 hybrid, however, does not appear to be capable of similar functions, 17 suggesting that different mechanisms may be involved in EWS-FLI1-induced tumorigenesis.
The second partner in the gene fusion, FLI1, belongs to the ets family of oncogenic transcription factors, 18, 19 whose members have been implicated in a number of human malignancies 8, 20, 21 and have been reported to mediate ras signaling. 22 Ets genes share a conserved DNA-binding domain that recognizes similar DNA sequences, but they have distinct expression patterns as well as other unique functional domains. However, in ES, where the DNA-binding domain appears to be an important determinant, only members of the ERG and PEA3 subclasses have been found to rearrange with EWS, perhaps indicating that important specificity determinants lie within the conserved DNA-binding domain.
The implication that the EWS/FLI1 gene fusion is responsible for the neoplastic phenotype in ES has led to attempts to control its expression and function. Antisense oligonucleotides have been used to minimize the expression levels of the oncogene, 13, 15 and dominantnegative plasmids have been used to block EWS/FLI1 function as a transactivator.
14 Recently we have identified ERF, a member of the ets family of transcription factors and a transcriptional repressor. 23 ERF is a mitogen-activated protein kinase-regulated protein that can suppress v-ets-induced tumorigenicity. Furthermore, phosphorylation-deficient ERF mutations can suppress ras-induced tumorigenicity and can arrest cells at the G 0 /G 1 phase of the cell cycle. 24 In this report, we describe our results using retroviral vectors expressing FLI1-ERF hybrid transcriptional repressors to block the transcriptional activation of potential EWS-FLI1 fusion protein targets. Our data indicate both that retroviral gene transfer of a FLI1-ERF hybrid can suppress the ES phenotype and that important specificity elements required for this suppression lie within the ets DNAbinding domain. These results suggest that use of ERF-FLI1, and other ERF chimeric proteins, may be a viable approach to blocking the oncogenic potential not only in ES, but also in other tumors in which the phenotype is dependent upon transcriptional inducers.
MATERIALS AND METHODS

Plasmids, proteins, and antibodies (Abs)
The FLI1/ERF hybrid was generated by inserting an in-frame ATG via an NcoI linker at the StyI site (amino acid 243) of the FLI1 gene. 19 The 439-bp EcoRI-RsaI fragment of the linkercontaining FLI1 sequence was fused at the XmnI site (amino acid 101) of the ERF sequence 23 to generate the FLI1/ERF hybrid. The ERF/FLI1 hybrid was generated by inserting an in-frame ATG via an NcoI linker at the SmaI site (amino acid 472) of the ERF gene. The 227-bp AvaI-HinfI fragment of the linker, containing the ERF sequence, was fused at the EcoRI site (amino acid 233) of the FLI1 sequence to generate the ERF/FLI1 hybrid. The hybrids as well as the wild-type (wt) ERF and FLI1 genes were cloned into pSG5 (Stratagene, La Jolla, Calif), pRc/RSV (Invitrogen, San Diego, Calif), and pLRNL 25 vectors. The in-frame fusion of the proteins was verified by sequencing as well as by in vitro protein production using the TnT (transcription and translation) cell-free system (Promega, Madison, Wis). The 650-bp EcoRI-HindIII fragment of FLI1 was used as the 3Ј-specific probe; the 480-bp BamHI-EcoRI fragment of FLI1 was used as the 5Ј-specific probe. The subcellular localization of the proteins was determined using anti-ERF- 23, 24 and anti-FLI1-specific Abs (rabbit polyclonal against the full-length FLI1 protein; D.K.W., unpublished data), 26 as described previously. The electrophoretic mobility shift assay was performed as described previously 23 using protein produced in vitro and the ETS1-3 27 -labeled oligonucleotide as a probe.
Cell line transfection and transformation
The RD-ES and SK-ES-1 cell lines were obtained from the American Type Culture Collection (ATCC) (Manassas, Va) and maintained in 85% RPMI 1640 medium, 15% fetal bovine sera (FBS), and 85% McCoy's 5a medium 15% FBS, respectively. NIH/3T3 and CRE cells were maintained in 92% Dulbecco's modified Eagle's medium and 8% bovine sera; the PA317 cells were maintained in 90% Dulbecco's modified Eagle's medium and 10% FBS. Helper-free viral stocks were prepared by transfecting the ecotropic packaging cell line CRE 28 , harvesting the transiently expressed virus, and infecting the amphotropic packaging cell line PA317. 29 Individual G418-resistant colonies of PA317 cells were isolated, expanded, and screened for the production of virus by NIH/3T3 infection. Stocks from the higher expressing PA317 clones, with titers of 5 ϫ 10 3 to 5 ϫ 10 4 colony-forming units/mL, were used for the infection of the EWS cell lines. Cell line infections were performed as described previously. 30 Infected or transfected SK-ES-1 and RD-ES cells were selected with 400 g/mL G418, and pools of colonies or individual clones were expanded and analyzed. The tumorigenic potential was determined after subcutaneous injection of SK-ES-1 cells in athymic mice. Animals were monitored twice a week for tumor development and general health conditions. The effect on transcription was analyzed in transient transfection assays as described previously. 23 A total of 0.5 g of the TK-GATA.CAT reporter plasmid was cotransfected into NIH/3T3 cells with 0.5 g of the pSG5-based expression construct described above and/or the ⌬EB-EWS/FLI1 expression plasmid 11 provided by Dr. J. Ghysdael, along with 1 g Rous sarcoma virus (RSV)-␤-galactosidase, to normalize for transfection variation.
RESULTS
Generation of FLI1-ERF chimeras
The EWS-FLI1 fusion product has been shown to be a potent transcriptional activator that can induce etsdependent promoters. We postulated that if the continuous presence of this activator is required for development of the ES phenotype, we might be able to suppress the phenotype by introducing an ets inhibitor into the cells. To test this hypothesis, we used ERF, an etsdomain protein that is a potent transcriptional repressor. ERF is capable of repressing transcription from promoters containing an ets-binding site (EBS) and of suppressing ets-induced tumorigenesis in the NIH/3T3 system. 23 Initial experiments with ERF alone failed to suppress the Ewing's phenotype in ES-derived cell lines (see below), suggesting that the presence of the FLI1 DNAbinding domain was important for both transformation and suppression. We had shown previously that the ERF repressor domain maintains its activity when transferred to a heterologous DNA-binding domain; 23 therefore, to directly address the specificity of the FLI1 DNA-binding domain in the ES phenotype, we generated two hybrids ( Fig 1A) . In the first (FLI1-ERF), we maintained the ERF structure and replaced the ERF DNA-binding domain (amino acids 1-101) with the FLI1 DNA-binding domain (amino acids 245-380). This construct could address the contribution of DNA-binding specificity to the possible suppression of the ES-transformed phenotype. The second hybrid (ERF-FLI1) retained the FLI1 part of the EWS-FLI1 hybrid (amino acids 233-451 of FLI1) and replaced the EWS portion with the repressor domain of ERF (amino acids 473-546), allowing us to test the role of the EWS portion of the EWS/FLI1 hybrid in the development of the Ewing's phenotype. The hybrid genes, as well as the parental ERF and FLI1, were cloned into expression vectors under the control of either the simian virus 40 (SV40) promoter (pSG5 vector), the RSV promoter (pRc/RSV), or the retroviral long terminal repeat (pLRNL).
The structural integrity, DNA binding, and transcription factor activity of the two hybrids were initially tested in parallel with the parental proteins. The in vitroproduced hybrid proteins had the expected sizes of ϳ80 kDa for FLI1-ERF and ϳ40 kDa for ERF-FLI1 ( Fig  1B) , confirming the in-frame fusion and the absence of dramatic structural changes. The in vitro-produced wt and hybrid proteins could bind the ETS1-3 oligonucleotide, 27 which contained the optimal EBS, with similar affinities (Fig 1C) , suggesting that fusion did not affect the structure or accessibility of the ets-DNA-binding domain. Furthermore, both wt ERF and the FLI1-ERF hybrid could be super-shifted by an anti-ERF-specific Ab (Fig 1C, first three lanes) , confirming the integrity of the hybrid. This Ab is directed against the amino terminus of the ERF protein 23 and does not recognize the ERF-FLI1 hybrid because the epitope is destroyed in this fusion. Consistent with previous observations, 10, 11 transient transfection assays in NIH/3T3 cells using an EBS-containing reporter construct indicated that EWS/ FLI1 was a much more potent transcriptional activator than FLI-1 (Fig 1D) . In contrast, both ERF/FLI1 hybrids, like ERF, 23 exhibited transcriptional repressor activity and could antagonize the EWS/FLI1-induced transcriptional activation of the recombinant promoter more effectively than wt ERF (Fig 1D) . The repression of the EWS/FLI1-induced activation was proportional to the relative amounts of the plasmids as well as to their affinity for the specific EBS present in the recombinant promoter (data not shown). The transactivation data in combination with the in vitro expression of the proteins also confirm the functional and structural integrity of the chimeras with regard to their ability to produce the expected protein in vitro and in vivo.
Expression of transgenes in ES cells
Two ES cell lines, RD-ES (HTB-166; ATCC) and SK-ES-1 (HTB-86; ATCC) were used as model systems to test the effects of the expression of the ERF and ERF-hybrid proteins on the EWS phenotype. We verified that both cell lines carry the EWS-FLI1 rearrangement by Northern blot analysis. Cell lines contained messages that hybridized to the 3Ј FLI1 probe, but not the 5Ј FLI1 probe, contained in the EWS-FLI1 rearrangement, (Fig 2) ; this was verified by reverse transcriptase-polymerase chain reaction with primers specific for the EWS-FLI1 mRNA (data not shown).
To test the effects of expression of the transcriptional repressors on the EWS phenotype, cells were infected either with the control retrovirus or with one carrying the ERF, FLI1, or FLI1/ERF hybrid genes. Stable, infected cells were selected with G418, and both pools and individual G418-resistant colonies were isolated and analyzed. The expression level of the introduced genes, as well as that of the relevant endogenous genes, was determined by Northern blot analysis. As probes, we used a 3Ј FLI1 fragment (see Materials and Methods), which can detect the wt FLI1 mRNA, the EWS/FLI1 chimeric transcript, and the FLI1-ERF hybrid, as well as a 5Ј FLI1 probe, which can detect only the wt FLI1 mRNA. We also used an ERF probe, which can detect both the wt ERF and the ERF-hybrids. The RNA expression level of the introduced genes, which was determined by densitometric analysis of the autoradiograms, suggested a moderate overexpression. In general, the level of expression was 1-to 10-fold greater than both the level of endogenous EWS/FLI1 mRNA (Fig 2,  3Ј FLI1 probe, lower bands) and the endogenous ERF transcript (Fig 2, ERF probe, lower bands) . It is of interest that the expression of the FLI1/ERF hybrid in SK-ES-1 cells is 2-fold lower than that of endogenous EWS/FLI1 (Fig 2, last lane, FLI1 /ERF), but is still sufficient to suppress the tumorigenic phenotype (see below). The EWS/FLI1, ERF, FLI1, and FLI1-ERF protein levels, which were determined by Western blotting using the specific FLI1 and ERF Abs, were consistent with the mRNA levels, suggesting minimal, if any, posttranslational effects (data not shown).
FLI1-ERF fusion suppresses the ES phenotype
The ES tumor-derived RD-ES cells normally grow as loosely attached clusters that form primitive cell junctions. Cells expressing exogenous FLI1 or ERF exhibited a morphology similar to the parental RD-ES cells, although their clustering was occasionally more evident, depending upon cell density and clonal variation. In contrast, expression of the FLI1/ERF hybrid induced a drastic change in cell morphology. FLI1/ERF-infected cells grew as a firmly attached monolayer, suggesting that these cells had acquired an increased tendency to adhere to the substrate (Fig 3) . This is a characteristic of many non-tumor cells and was an indication that moderate expression of the FLI1/ERF hybrid could suppress some aspects of the ES phenotype. The other ESderived cell line, SK-ES-1, grows as a monolayer; we did not observe any significant morphological changes when these cells were infected with any of the three recombinant retroviruses (data not shown).
A stronger indication of the tumorigenic potential of a cell, however, is tumor development after injection into athymic mice. Although neither RD-ES cells nor those cells overexpressing ERF, FLI1, or FLI1/ERF exhibited any tumorigenic potential in this assay (data not shown), the parental SK-ES-1 cells were highly tumorigenic when injected into nude mice. In addition, vectorinfected, FLI1-infected, and ERF-infected SK-ES-1 cells were equally tumorigenic, and the tumors grew at similar rates ( Table 1 ), suggesting that, as in the case of the RD-ES cell morphology (see above), expression of the wt ERF and FLI1 genes was not able to suppress the tumorigenic phenotype. However, the SD-ES-1 cells expressing the FLI1/ERF hybrid developed tumors much more slowly, requiring almost twice as much time for palpable tumors to appear ( Table 1 ). All of the cell lines had similar proliferation rates in culture, so this delay could not be explained by growth rate effects. Furthermore, it was difficult to establish cell lines from the tumors that did arise, and we observed extensive cell death during the drug selection process, suggesting that many of the cells forming the tumor did not contain the transgene. In all cases we were able to finally establish cell lines expressing the introduced genes, but significantly, the level of fusion gene mRNA in the FLI1/ERFinfected SK-ES-1 cells was much lower than that seen in other transgene-expressing cell lines, and was also lower than the level of endogenous EWS/FLI1 expression. This low level of expression, although sufficient to decrease the tumorigenic potential of the SK-ES-1 cells, may be the cause of the incomplete suppression of the tumorigenic phenotype in these cells.
The incomplete suppression of the SK-ES-1 tumorigenicity could also be a result of the subcellular localization of the FLI1-ERF hybrid. We have shown that the intracellular distribution of ERF is controlled by Erkdependent phosphorylation in response to the proliferation stage of the cell. 24 We examined the subcellular distribution of the FLI1/ERF hybrid and found it to be identical with wt ERF. Thus FLI1/ERF is localized in the cytoplasm of proliferating cells and in the nucleus of serum-arrested cells (Fig 4) . This pattern is unique to the FLI1-ERF hybrid, because both EWS/FLI1 10 and FLI1 are nuclear proteins and their localization has not been reported to change with the cell cycle stage. The localization of the FLI1-ERF hybrid is also consistent with its transcription repressor and suppressor activity (Table 1 versus Table 2 ) and suggests that even the temporary presence of this hybrid protein in the nucleus was adequate to suppress the Ewing's phenotype.
To overcome the potential localization and low expression level problems and to generate a hybrid repressor that would interfere more directly with EWS/FLI1 function, we tested constructs expressing the ERF/FLI1 hybrid (Fig 1) under the control of two potent promoters derived fromSV40 and RSV (see above and Fig 1) . In this hybrid, the FLI1 structure of the EWS/FLI1 protein is maintained, but the ERF repressor domain replaces the EWS activation domain. Significantly, this construct also lacks the region responsible for the control of ERF localization. We introduced this hybrid into the two ES-derived cell lines, using cotransfection with a selectable marker in the case of the SV40-promoter driven construct. (The RSV promoter-driven construct contains an internal neo-selectable marker.) In replicateindependent experiments, transfections with the plasmids carrying the hybrid gene yielded 10-to 20-fold fewer colonies than the vector control (116 colonies for ERF/FLI1 constructs versus 1938 colonies for the vectors; Table 2 ). Furthermore, we were unable to obtain any colonies of SK-ES-1 or RD-ES cells that express this -expressing plasmids (a,a'),  FLI1-expressing plasmids (b,b') , and FLI1/ERF-expressing plasmids (c,c') were transfected into NIH/3T3 cells. The subcellular localization of the protein was detected by indirect immunofluorescence in exponentially growing cells (a-c) or serum-arrested cells  (a'-c') with anti-ERF-specific (a,a';c,c') and anti-FLI1 specific (b,b' ) Abs. *A total of 500,000 G418-selected SK-ES-1 cells, generated after infection with the indicated virus, were injected subcutaneously into athymic mice. The animals were monitored twice a week for tumor development and general health.
hybrid protein (none of 96 clones tested by immunoblotting; Table 2 ). These two observations suggested that this potent transcriptional repressor hybrid totally blocks the ability of the cells to form colonies in tissue culture. This was also true when the ERF/FLI1 constructs were introduced in NIH/3T3 and HeLa cells, suggesting that the nonregulatable form of this repressor may be toxic. In contrast, the FLI1/ERF hybrid was successfully expressed in a number of cell types (HeLa, K562, FDC-P2, NIH/3T3) without any adverse effects (data not shown).
DISCUSSION
The EWS/FLI1 fusion gene product is necessary for the maintenance of the transformed phenotype of ES tumors; in addition, it is highly tumorigenic in model systems. 10, 11 For these reasons, its repression has become an attractive target for the control of ES tumorigenesis. [13] [14] [15] In this report, we show that it is possible, using retroviral gene transfer, to suppress the ES phenotype by inducing the expression of a specific transcriptional repressor that can antagonize EWS/FLI1 activity. We also show that this suppression occurs even at low levels of transgene expression.
ERF, a member of the ets gene family, is an active repressor, and we have shown previously that it contains a domain that can exhibit transcriptional repressor activity when attached to a heterologous DNA-binding domain. 23 Furthermore, substoichiometric amounts of the ERF repressor can effectively repress transcription in the presence of an activator that recognizes the same targets. Here we have shown that introduction of a hybrid protein containing the FLI1 DNA-binding domain linked to the regulatory and repressor domains of ERF resulted in suppression of the tumorigenic phenotype of ES. In suppressed cells, the level of endogenous EWS/FLI1 transcript (and protein; our unpublished observations) was unaffected, suggesting that the suppression was not due to decreased oncogene levels, but rather to the decrease of its transcriptional effect on its targets. ERF has been shown to be important for the G 1 transition, and has been shown to enter the nucleus at specific stages of the cell cycle. 24 The FLI1/ERF protein demonstrates a similar mitogen-activated protein kinase-dependent subcellular localization, suggesting that temporary entry of the FLI1/ERF protein into the nucleus is sufficient to suppress the ES phenotype. Because FLI1/ERF and EWS/FLI1 have opposite effects on transcription, the oncogenic activity of the EWS/FLI1 fusion protein is likely to involve activation of genes that can promote or allow inappropriate progression into the G 1 phase of the cell cycle. However, the temporary entry of FLI1/ERF into the nucleus may also contribute to the incomplete suppression we observed. Indeed, ERF/ FLI1, a hybrid that contains only the repressor domain of ERF and the DNA-binding domain of FLI1 and whose localization in the nucleus, is independent of the cell cycle; in addition, ERF/FLI1 appeared to totally inhibit cell growth in ES, NIH/3T3, and HeLa cells. This is consistent with our observation that this fusion is a more potent transcriptional repressor than the FLI1/ ERF hybrid. However, quantitative effects may also contribute to these responses, because transfection may have introduced high levels of this hybrid in the transfected cells, and the hybrid transcript is driven by stronger promoters.
Although ets proteins constitute one of the more extended families of transcription factors in mammalian cells, only a limited number of ets domain proteins appear to be involved in rearrangements with the EWS gene. This could be due to the localization of other ets genes in regions with lower recombination frequencies. However, ets genes have been found to recombine with other genes, [31] [32] [33] [34] suggesting that they are capable of recombination and rearrangement. It is more likely that only specific ets-EWS recombinations generate hybrid proteins that recognize specific targets that subsequently promote tumor formation. [35] [36] [37] [38] It is likely that specific ets domains recognize unique cellular targets. This hypothesis is also supported by our finding that the FLI1/ ERF hybrid, but not wt ERF, is able to suppress the ES phenotype, despite their similarities in expression level and subcellular compartmentalization. Alignment of the ets genes found rearranged with the EWS genes (Fig 5) reveals that two amino acids within the conserved DNA-binding domain are unique among them (methionine 348 and tyrosine 356 in the FLI1 sequence; indicated by open arrows in Fig 5) . Random mutagenesis has shown that mutations at these residues drastically affect the DNAbinding activity. 39 These amino acids are not directly involved in protein-DNA contact, 40 and it is likely that they affect interactions with other proteins important for target recognition. The contribution by the DNA-binding domain may be detectable in our study because the levels of protein expression were similar to normal cellular levels. Under these more physiological conditions, we may have been able to detect small, but important, differences that have been obscured previously by overexpression. This is one of the few cases in which functional distinctions can be made among ets-DNA-binding domains, and it is consistent with in vivo studies indicating that small differences in the structure and activity of the fusion protein can be corre- lated with phenotypic differences. 12, 41, 42 Other studies, however, have failed to detect DNA-binding-related differences. 43, 44 Previous attempts to use molecular methods to suppress the EWS/FLI1 tumorigenic activity have involved either antisense approaches or the introduction of constructs expressing high levels of FLI1 DNA-binding domains, which can act as competitors by occupying the same targets as the EWS/FLI1 protein. [13] [14] [15] Both approaches resulted in decreased tumorigenicity, supporting the hypothesis that the ES phenotype results from the inappropriate activation of genes controlled by FLI1 or related members of the ets family of transcription factors. However, these approaches involve overexpression of the antagonizing factor, which is not easy to achieve under in vivo conditions, and which may also impair the normal physiological function of the FLLI gene and produce generalized toxic effects. Similar effects are probably responsible for our inability to obtain stable clones overexpressing the ERF/FLI1 fusion protein, which is a very potent transcriptional repressor, not only in ES cells, but also in other normal or transformed cell types (unpublished data).
In contrast, we were successful with an approach using an active repressor that can effectively suppress the ES phenotype at expression levels lower than the transforming gene and that employs retroviral-mediated transfer for more effective gene delivery. Furthermore, the active hybrids contain the ERF domain that controls subcellular localization, allowing for the generation of repressor proteins whose functional activity can be modulated at several levels. Both inhibition of Erk activity as well as introduction of mutations that affect the ERF subcellular localization can generate a range of repressors with increased nuclear localization and thus increased repressor activity. 24 It has been suggested that "the ideal cancer therapy would accommodate the specific biology of a tumor and be based on understanding the mechanisms of malignancy." 45 In this sense, ERF repressor hybrids, with the unique potential to be regulated both quantitatively and by extracellular signals, may be an approach that could be valuable in the ES system, as well as other systems that involve inappropriate transcription factor activation. 
